←Back to Expert Scholars
Translational Medicine / 转化医学mRNA Cancer Vaccines, CTA Targeting
Ugur Sahin
MD
🏢BioNTech🌐Germany
CEO and Co-founder
100
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Ugur Sahin co-founded BioNTech and pioneered mRNA cancer vaccines targeting cancer-testis antigens and personalized neoantigens. His work on NY-ESO-1 and MAGE mRNA vaccines, alongside personalized FixVac and IVAC platforms, has redefined therapeutic cancer vaccine development.
Share:
🧪Research Fields 研究领域
mRNA cancer vaccine
NY-ESO-1 vaccine
MAGE vaccine
personalized neoantigen
BioNTech
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Ugur Sahin 的研究动态
Follow Ugur Sahin's research updates
留下邮箱，当我们发布与 Ugur Sahin（BioNTech）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment